Evidence map›Paper›PMID 24006152›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2014

Test-retest reliability of [11C]AZ10419369 binding to 5-HT(1B) receptors in human brain.

Magdalena Nord, Sjoerd J Finnema, Martin Schain, Christer Halldin, Lars Farde

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. First-in-Humans Brain PET Imaging of the GluN2B-ContainingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  8. Radiotracers for the Central Serotoninergic System.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  9. Serotonin 1B receptor density mapping of the human brainstem using positron emission tomography and autoradiography.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022
    Article
  10. Early stopping in clinical PET studies: How to reduce expense and exposure.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. [EJNMMI research · 2018
    Article
  16. Article
  17. Test-retest reproducibility of [EJNMMI research · 2017
    Article
  18. Article
  19. Review
  20. Test-retest reliability of the novel 5-HT1B receptor PET radioligand [11C]P943.European journal of nuclear medicine and molecular imaging · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Magdalena NordDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Psychiatric Research, R5:00, Karolinska University Hospital, SE-17176, Stockholm, Sweden, Magdalena.Nord@ki.se.
Sjoerd J Finnema
Martin Schain
Christer Halldin
Lars Farde
Karolinska Institutet · SEKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose[(11)C]AZ10419369 is a recently developed 5-HT1B receptor radioligand that is sensitive to changes in endogenous serotonin concentrations in the primate brain. Thus, [(11)C] AZ10419369 may serve as a useful tool in clinical studies of the pathophysiology and pharmacological treatment of diseases related to the serotonin system, such as depression and anxiety disorders. The aim of this study was to evaluate the test-retest reliability of [(11)C]AZ10419369.

methodsEight men were examined with PET and [(11)C] AZ10419369 twice on the same day. The binding potentials (BPND) of [(11)C]AZ10419369 in selected serotonergic projection areas and in the raphe nuclei (RN) were determined using the simplified reference tissue model, and for comparison also using a wavelet-aided parametric imaging approach. The BPND values obtained from the first and second PET scans were compared by means of descriptive statistics, difference, absolute variability and intraclass correlation coefficient.

resultsSimilar BPND values were obtained with the two methods. The absolute mean differences in BPND between PET 1 and PET 2 were less than 3% in all serotonergic projection regions. Absolute variabilities were low in cortical regions (5 - 7%), low to moderate (7 - 14%) in subcortical regions, but higher (20%) in the RN.

conclusionThe BPND of [(11)C]AZ10419369 is highly reproducible in cortical regions and satisfactory in subcortical projection areas. The variability in the RN is higher. Thus larger sample sizes or larger divergences are required to assess a potential difference between subjects or between experimental conditions in this region.

Indexed as

AdultBenzopyransData Interpretation, StatisticalHumansMaleMorpholinesPiperazinesPositron-Emission TomographyProtein BindingRadiopharmaceuticalsRaphe NucleiReceptor, Serotonin, 5-HT1BReproducibility of Results5-methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-morpholin-4-yl-phenyl)amideBenzopyransMorpholinesPiperazinesRadiopharmaceuticalsReceptor, Serotonin, 5-HT1B

Identifiers

PMID24006152
OpenAlexW2088396538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.